Xeris Biopharma Holdings Inc
XERS
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.37B
Close$
$2.89
65.3% downside
Current Fair Value
65.3% downsideOvervalued by 65.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.37 Billion |
|---|---|
| Enterprise Value | $1.54 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | 0.85 |
| Outstanding Shares | 172,823,455 |
Return
| Return on Equity | 176.34% |
|---|---|
| Return on Assets | -4.17% |
| Return on Invested Capital | 0.71% |
Valuation & Multiples
| P/E Ratio | -81.67 |
|---|---|
| PEG | -5.4 |
| Price to Sales | 8.33 |
| Price to Book Ratio | -8.33 |
| Enterprise Value to Revenue | 4.58 |
| Enterprise Value to EBIT | 976.33 |
| Enterprise Value to Net Income | -90 |
| Total Debt to Enterprise | 0.19 |
| Debt to Equity | -29.74 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$0.01
Average shareholder expectationRevenue Estimate
$90.13 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.02
Average shareholder expectationRevenue Estimate
$101.56 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 69.46% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 14.78%▼ 48.61% |
|---|---|
| Total Invested | $199.85M▼ 67.30% |
| Investors Holding | 80▼ 164.00% |
ESG Score
No data
About Xeris Pharmaceuticals Inc
CEO: paul Edick